Generative Artificial Intelligence (Gen AI) can rapidly and accurately screen patients for clinical trial eligibility, according to a new study from Mass General Brigham researchers. Such technology could make it faster and cheaper to evaluate new treatments and, ultimately, help bring successful ones to patients.